维得利珠单抗相关肺毒性1例并文献分析

梁瑜; 丁雪丽; 武军; 全香花; 赵俊; 张传洲; 姜曼

doi:10.6039/j.issn.1001-0408.2024.20.19

您当前的位置：

首页 >

文章列表页 >

维得利珠单抗相关肺毒性1例并文献分析

药师与药学服务 | 更新时间：2024-10-25

- 维得利珠单抗相关肺毒性1例并文献分析
- Vedolizumab-associated lung toxicity：a case report and literature analysis
- 中国药房 2024年35卷第20期页码：2552-2558
- 作者机构：
  
  1.青岛大学附属医院药学部，山东青岛　266003
  2.青岛大学附属医院消化内科，山东青岛　266003
- 作者简介：
  
  副主任药师，硕士。研究方向：临床药学。电话：0532-82912182。E-mail：liangyu2791@163.com
  副主任药师，博士。研究方向：临床药学。电话：0532-82912182。E-mail：jiangman@qdu.edu.cn
- 基金信息：
  
  山东省自然科学基金项目(ZR2023MH097);山东省医药卫生科技发展计划项目(202102040497)
- DOI：10.6039/j.issn.1001-0408.2024.20.19
  中图分类号： R969.3
- 纸质出版日期：2024-10-30，
  
  收稿日期：2024-03-21，
  
  修回日期：2024-08-27，
- 稿件说明：
移动端阅览
梁瑜,丁雪丽,武军等.维得利珠单抗相关肺毒性1例并文献分析 ^Δ[J].中国药房,2024,35(20):2552-2558.

LIANG Yu,DING Xueli,WU Jun,et al.Vedolizumab-associated lung toxicity：a case report and literature analysis[J].ZHONGGUO YAOFANG,2024,35(20):2552-2558.
梁瑜,丁雪丽,武军等.维得利珠单抗相关肺毒性1例并文献分析 ^Δ[J].中国药房,2024,35(20):2552-2558. DOI： 10.6039/j.issn.1001-0408.2024.20.19.

LIANG Yu,DING Xueli,WU Jun,et al.Vedolizumab-associated lung toxicity：a case report and literature analysis[J].ZHONGGUO YAOFANG,2024,35(20):2552-2558. DOI： 10.6039/j.issn.1001-0408.2024.20.19.

摘要

目的

介绍1例维得利珠单抗（VDZ）致间质性肺炎的病例，汇总分析该药相关肺毒性的发生特点，为临床安全用药提供参考。

方法

从临床药师角度出发，回顾性分析1例VDZ致间质性肺炎患者的诊治过程，并进行不良反应相关性分析；检索中国知网、维普网、PubMed、Web of Science等中英文数据库，对VDZ相关肺毒性的病例报道进行汇总分析。

结果

该患者在使用VDZ期间发生间质性肺炎，予抗菌药物经验性抗感染治疗无改善；停用VDZ并予甲泼尼龙治疗后，患者的症状及影像学检查均有改善但仍提示间质性肺炎。经Naranjo’s不良反应评估量表评估并根据我国《药品不良反应报告和监测工作手册》判断，VDZ与间质性肺炎的关联性均为“很可能”。文献分析结果显示，纳入的29例患者（含本文报道的患者）中，男性19例、女性10例，平均年龄（49.24±17.06）岁；肺毒性主要包括VDZ相关性肺炎、嗜酸性粒细胞肺炎、肺肉芽肿或坏死性结节、间质性肺损伤等，多发生在用药后24周以内（58.62%），主要临床表现为咳嗽、呼吸困难、发热等；绝大多数患者经停药和/或给予糖皮质激素等治疗后好转或康复，1例患者因呼吸衰竭死亡。

结论

肺毒性为VDZ较罕见的不良反应，起病隐匿且症状无特异性。一旦患者出现咳嗽、呼吸困难等症状，临床应早期判断、及时停药，并给予糖皮质激素等对症治疗，以保障患者用药安全。

Abstract

OBJECTIVE

To introduce a case of interstitial pneumonia induced by vedolizumab （VDZ）， summarize and analyze the characteristics of the occurrence of VDZ-associated lung toxicity， and provide a reference for the clinically safe use of drugs.

METHODS

From the perspective of clinical pharmacists， the diagnosis and treatment of a case of VDZ-induced interstitial pneumonia were retrospectively analyzed， and the association of adverse drug reactions （ADR） was analyzed. Retrieving from Chinese and English databases such as CNKI， VIP， PubMed and Web of Science， case reports of VDZ-associated lung toxicity were summarized and analyzed.

RESULTS

The patient developed interstitial pneumonia during the use of VDZ and empirical anti-infective therapy with antibiotics was ineffective. After withdrawal of VDZ and treatment with methylprednisolone， symptoms and imaging examinations improved， but interstitial pneumonia still existed. According to Naranjo’s ADR evaluation scale and based on

China Adverse Drug Reaction Reporting and Monitoring Manual

， the association between VDZ and interstitial pneumonia was “very likely”. Results of the lite

rature analysis showed that among 29 involved patients （including the patient reported in this article）， there were 19 males and 10 females， with an average age of （49.24±17.06） years. Lung toxicity mainly included VDZ-associated pneumonia， eosinophilic pneumonia， pulmonary granulomas or necrobiotic nodules， interstitial lung injury， etc.， which mostly occurred ≤24 weeks after medication （58.62%）. The main clinical manifestations included cough， dyspnea and fever. The vast majority of patients improved or recovered after drug withdrawal and/or glucocorticoid treatment， but one patient died of respiratory failure.

CONCLUSIONS

Lung toxicity is a rare ADR of VDZ with insidious onset and nonspecific symptoms. Once patients experience symptoms such as cough and dyspnea， early diagnosis，timely drug withdrawal，and symptomatic treatment measures such as glucocorticoid should be taken to ensure medication safety.

关键词

维得利珠单抗肺毒性间质性肺炎药物不良反应文献分析

Keywords

lung toxicityinterstitial pneumoniaadverse drug reactionliterature analysis

references

WYANT T，FEDYK E，ABHYANKAR B. An overview of the mechanism of action of the monoclonal antibody vedolizumab[J]. J Crohns Colitis，2016，10（12）：1437-1444.

Takeda. Entyvio®（vedolizumab）approved in Japan for the treatment of patients with moderately to severely active Crohn’s disease[EB/OL].（2019-05-22）[2024-03-16]. https：//www.takeda.com/newsroom/newsreleases/2019/entyvio-vedolizumab-approved-in-japan-for-the-treatment-of-patients-with-moderately-to-severely-active-crohns-disease/https://www.takeda.com/newsroom/newsreleases/2019/entyvio-vedolizumab-approved-in-japan-for-the-treatment-of-patients-with-moderately-to-severely-active-crohns-disease/.

周青杨，钱家鸣. 新型肠道选择性生物制剂治疗炎症性肠病的研究进展[J]. 中华消化杂志，2020，40（2）：141-144.

ZHOU Q Y，QIAN J M. Research progress of new intestinal selective biological agents in the treatment of inflammatory bowel disease[J]. Chin J Dig，2020，40（2）：141-144.

梁瑜，孙加琳，孟真，等. 维得利珠单抗致34例不良反应文献分析[J]. 中国医院药学杂志，2022，42（12）：1243-1248.

LIANG Y，SUN J L，MENG Z，et al. Literature analysis of 34 cases of adverse drug reactions induced by vedolizumab[J]. Chin J Hosp Pharm，2022，42（12）：1243-1248.

普燕芳，陈力，曹玮. 基于FAERS数据库的维得利珠单抗不良事件信号挖掘与分析[J]. 中南药学，2023，21（11）：3062-3067.

PU Y F，CHEN L，CAO W. Data mining and analysis of adverse event signals of vedolizumab based on FAERS database[J]. Cent South Pharm，2023，21（11）：3062-3067.

AUDI A，KHOUDARI G，DEVGUN S. Vedolizumab associated pneumonitis in a 60 year old male with refractory ulcerative colitis[J]. Am J Gastroenterol，2016，111：S820.

NARANJO C A，BUSTO U，SELLERS E M，et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther，1981，30（2）：239-245.

国家食品药品监督管理局药品安全监管司，国家药品不良反应监测中心.药品不良反应报告和监测工作手册[M].北京：国家药品不良反应监测中心，2012：49-51.

Department of Drug Supervision，China Food and Drug Administration，National Adverse Drug Reaction Monito-ring Center. Manual on reporting and monitoring of adverse drug reaction[M]. Beijing：National Adverse Drug Reaction Monitoring Center，2012：49-51.

LISSNER D，GLAUBEN R，ALLERS K，et al. Pulmonary manifestation of Crohn’s disease developed under treatment with vedolizumab[J]. Am J Gastroenterol，2018，113（1）：146-148.

NAMBIAR S，KARIPPOT A，OLIVER T. Vedolizumab-associated acute respiratory distress syndrome[J]. Am J Ther，2018，25（5）：e592-e593.

CATTANEO R，COLOMBO S，BIAGIOTTI S，et al. A rare case of pneumonia in patients with ulcerative colitis treated with vedolizumab[J]. Italian J Med，2019，13（Suppl. 2）：69.

LAWRENCE R，KLINGS E S. Management of chronic eosinophilic pneumonia with mepolizumab[J]. Am J Respir Crit Care Med，2019，199：A1522.

MYC L A，GIRTON M R，STOLER M H，et al. Necro-biotic pulmonary nodules of Crohn’s disease in a patient receiving vedolizumab[J]. Am J Respir Crit Care Med，2019，199（1）：e1-e2.

DAVIDSON R，HERSHBERGER D. The rise of respiratory manifestations of inflammatory bowel disease：can treatment be too selective?[J]. Chest，2019，156（4）：A1819.

AJMAL Z，CHUNG J，ZAHRA F T，et al. Necrobiotic pulmonary nodules in a patient with Crohn’s disease recei-ving vedolizumab[J]. Chest，2020，158（4）：A2003-A2004.

DE BACKER E，BODE H，BAERT F. New-onset diffuse parenchymal lung disease in a 52-year-old woman with ulcerative colitis[J]. Gastroenterology，2020，158（3）：478-479.

ABU SHTAYA A，COHEN S，KOGAN Y，et al. Crohn’s disease with atypical extra-intestinal manifestations deve-loping under treatment with vedolizumab[J]. Eur J Case Rep Intern Med，2021，8（3）：002265.

SEDANO R，DHALIWAL I，RAMSEWAK D，et al. Drug-induced lupus associated with vedolizumab in a patient with Crohn’s disease[J]. Inflamm Bowel Dis，2021，27（4）：e47-e48.

RIZOS E D，ANTONOGIANNAKI E M，CHATZIDAKIS A，et al. Vedolizumab-induced acute interstitial lung injury in a 39-year-old male with ulcerative colitis[J]. Eur J Gastroenterol Hepatol，2021，33（1S Suppl. 1）：e1057-e1059.

PATEL P，OCHIENG P，SHETTY A. Another sequalae of COVID? Not so fast[J]. Am J Respir Crit Care Med，2022，205：A4565.

ZHU W W，ZHAO T H，WEI J，et al. Case report：eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis[J]. Front Med，2022，9：942237.

PUGLIESE D，PRIVITERA G，SCHEPIS T，et al. Drug-related pneumonitis in patients receiving vedolizumab therapy for inflammatory bowel disease[J]. Clin Gastroenterol Hepatol，2022，20（6）：e1483-e1487.

DULANEY D，DAVE P，WALSH S，et al. Noninfectious pulmonary complications associated with anti-integrin therapy：a case report and systematic review of the literature[J]. Inflamm Bowel Dis，2022，28（3）：479-483.

ZHANG J，LIU M H，GAO X，et al. Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis：a case report[J]. World J Clin Cases，2022，10（5）：1716-1722.

CUCINOTTA U，DIPASQUALE V，COSTA S，et al. Vedolizumab-associated pulmonary manifestations in chi-ldren with ulcerative colitis[J]. J Clin Pharm Ther，2022，47（2）：254-256.

FARIA L M，OLIVEIRA M M，FARIA A A，et al. Late onset vedolizumab-induced eosinophilic pneumonia in a patient with ulcerative colitis[J]. Eur J Gastroenterol Hepatol，2023，35（4）：513-514.

LAMB C A，O’BYRNE S，KEIR M E，et al. Gut-selective integrin-targeted therapies for inflammatory bowel disease[J]. J Crohns Colitis，2018，12（Suppl.2）：S653-S668.

BRANDT E B，ZIMMERMANN N，MUNTEL E E，et al. The α4bβ7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine[J]. Clin Exp Allergy，2006，36（4）：543-553.

MASSART A，HUNT D P. Pulmonary manifestations of inflammatory bowel disease[J]. Am J Med，2020，133（1）：39-43.

王晨玉，黄元楷，席晓宇. 我国临床药师与医师协作概念的探讨[J]. 中国药房，2023，34（4）：487-492.

WANG C Y，HUANG Y K，XI X Y. Discussion on the concept of collaboration between clinical pharmacists and physicians in China[J]. China Pharm，2023，34（4）：487-492.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肝癌合并HBV感染患者使用富马酸替诺福韦二吡呋酯致肾损伤1例并文献分析

司美格鲁肽致药品不良反应文献分析

阿帕替尼上市后的ADR文献分析

临床药师参与1例左氧氟沙星致超敏反应的药学监护及文献分析

地舒单抗相关非典型骨折的文献分析